[Federal Register Volume 61, Number 127 (Monday, July 1, 1996)]
[Notices]
[Pages 33927-33928]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 96-16770]


-----------------------------------------------------------------------


DEPARTMENT OF HEALTH AND HUMAN SERVICES

Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This notice announces a forthcoming meeting of a public 
advisory committee of the Food and Drug Administration (FDA). This 
notice also summarizes the procedures for the meeting and methods by 
which interested persons may participate in open public hearings before 
FDA's advisory committees.

    FDA has established an Advisory Committee Information Hotline (the 
hotline) using a voice-mail telephone system. The hotline provides the 
public with access to the most current information on FDA advisory 
committee meetings. The advisory committee hotline, which will 
disseminate current information and information updates, can be 
accessed by dialing 1-800-741-8138 or 301-443-0572. Each advisory 
committee is assigned a 5-digit number. This 5-digit number will appear 
in each individual notice of meeting. The hotline will enable the 
public to obtain information about a particular advisory committee by 
using the committee's 5-digit number. Information in the hotline is 
preliminary and may change before a meeting is actually held. The 
hotline will be updated when such changes are made.
MEETING: The following advisory committee meeting is announced:
Advisory Committee for Reproductive Health Drugs
    -Date, time, and place. July 19, 1996, 9 a.m., FDA Technical 
Center, 16071 Industrial Dr., Gaithersburg, MD. Attendees should allow 
time to proceed through security procedures. Admission to the facility 
by public participants will be available on a first come, first serve 
basis, and will be limited to approximately 200, the number of seats 
available to the public in the conference room. There will be an 
overflow room with both audio and video link to the meeting. The 
overflow room is located at the Hilton Hotel, 620 Perry Pkwy., 
Gaithersburg, MD.
    -Type of meeting and contact person. Open committee discussion, 9 
a.m. to 1:30 p.m.; open public hearing, 1:30 p.m. to 3:30 p.m., unless 
public participation does not last that long; open committee 
discussion, 3:30 p.m. to 5 p.m.; Philip A. Corfman, Center for Drug 
Evaluation and Research (HFD-580), Food and Drug Administration, 5600 
Fishers Lane, rm. 14B-04, Rockville, MD 20857, 301-443-3510, FAX 301-
443-9282, or e-mail <a href="/cdn-cgi/l/email-protection#6f051a03165e562f0c0b0a1d41090b0e41080019"><span class="__cf_email__" data-cfemail="5b312e37226a621b383f3e29753d3f3a753c342d">[email protected]</span></a>. Information concerning the 
meeting is available from FDA Advisory Committee Information Hotline, 
1-800-741-8138 (301-443-0572 in the Washington, DC area), Advisory 
Committee for Reproductive Health Drugs, code 12537. Please call the 
hotline for information concerning any possible changes.
    -General function of the committee. The committee reviews and 
evaluates data on the safety and effectiveness of marketed and 
investigational human drugs for use in the practice of obstetrics, 
gynecology, and related specialties.
    Agenda--Open public hearing. Interested persons may present data, 
information, or views, orally or in writing, on issues pending before 
the committee. Those desiring to make formal presentations should 
notify the contact person in writing by mail, e-mail, or fax no later 
than 5 p.m., EDT on July 12, 1996, with a brief statement of the 
general nature of the evidence or arguments they wish to present, the 
names, telephone numbers, and addresses of proposed participants, and 
an indication of the approximate time required to make their comments. 
The time for presentations will be allotted equitably, and will depend 
on how many individuals give advance notice within the time indicated 
of their intention to speak. In the interest of time, the agency may 
require persons with common interests to make joint presentations.
    -Open committee discussion. The committee will discuss the new drug 
application for mifepristone for the interruption of early pregnancy.
    FDA public advisory committee meetings may have as many as four 
separable portions: (1) An open public hearing, (2) an open committee 
discussion, (3) a closed presentation of data, and (4) a closed 
committee deliberation. Every advisory committee meeting shall have an 
open public hearing portion. Whether or not it also includes any of the 
other three portions will depend upon the specific meeting involved. 
There are no closed portions for the meetings announced in this notice. 
The dates and times reserved for the open portions of each committee 
meeting are listed above.
    The open public hearing portion of each meeting shall be at least 1 
hour long unless public participation does not last that long. It is 
emphasized, however, that the 1 hour time limit for an open public 
hearing represents a minimum rather than a maximum time for public 
participation, and an open public hearing may last for whatever longer 
period the committee chairperson determines will facilitate the 
committee's work.
    Public hearings are subject to FDA's guideline (subpart C of 21 CFR 
part 10) concerning the policy and procedures for electronic media 
coverage of FDA's public administrative proceedings, including hearings 
before public advisory committees under 21 CFR part 14. Under 21 CFR 
10.205, representatives of the electronic media may be permitted, 
subject to certain limitations, to videotape, film, or otherwise record 
FDA's public administrative proceedings, including presentations by 
participants.
    Meetings of advisory committees shall be conducted, insofar as is 
practical, in accordance with the agenda published

[[Page 33928]]

in this Federal Register notice. Changes in the agenda will be 
announced at the beginning of the open portion of a meeting.
    Any interested person who wishes to be assured of the right to make 
an oral presentation at the open public hearing portion of a meeting 
shall inform the contact person listed above in writing, prior to the 
meeting.
    The agenda, the questions to be addressed by the committee, and a 
current list of committee members will be available at the meeting 
location on the day of the meeting.
    Transcripts of the open portion of the meeting may be requested in 
writing from the Freedom of Information Office (HFI-35), Food and Drug 
Administration, rm. 12A-16, 5600 Fishers Lane, Rockville, MD 20857, 
approximately 15 working days after the meeting, at a cost of 10 cents 
per page. The transcript may be viewed at the Dockets Management Branch 
(HFA-305), Food and Drug Administration, rm. 1-23, 12420 Parklawn Dr., 
Rockville, MD 20857, approximately 15 working days after the meeting, 
between the hours of 9 a.m. and 4 p.m., Monday through Friday. Summary 
minutes of the open portion of the meeting may be requested in writing 
from the Freedom of Information Office (address above) beginning 
approximately 90 days after the meeting.
    This notice is issued under section 10(a)(1) and (2) of the Federal 
Advisory Committee Act (5 U.S.C. app. 2), and FDA's regulations (21 CFR 
part 14) on advisory committees.

    Dated: June 25, 1996.
Michael A. Friedman,
Deputy Commissioner for Operations.
[FR Doc. 96-16770 Filed 6-28-96; 8:45 am]
BILLING CODE 4160-01-F


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>